| Overview |
| bs-2996R |
| CACNB2 Polyclonal Antibody |
| ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Dog, Horse, Chicken, Rabbit |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human CACNB2 |
| 551-655/655 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| 783 |
| Cytoplasm, Cell membrane |
| Voltage-dependent L-type calcium channel subunit beta-2; CAB2; Cacnb2; Cacnlb2; VDCC-L Beta; Calcium channel voltage-dependent subunit beta 2; calcium channel, voltage-dependent, beta 2 subunit; calcium channel beta 2c subunit; calcium channel L-type beta 2 subunit; CACB2_HUMAN. |
| CACNB2 is a subunit of a voltage-dependent calcium channel protein which is a member of the voltage-gated calcium channel superfamily, expressed in the CNS. The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting. It was originally identified as an antigen target in Lambert-Eaton myasthenic syndrome which is an autoimmune disorder. Mutations in this gene are associated with Brugada symdrome. Alternatively spliced variants have been identified for this gene. |
| Application Dilution |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz